ReviewPharmaceuticals (Basel, Switzerland)2010
Allosteric Modulation of Muscarinic Acetylcholine Receptors.
Review in Pharmaceuticals (Basel, Switzerland), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 41 citations in OpenAlex.
- Bile Acids Are Potential Negative Allosteric Modulators of M1 Muscarinic Receptors.Biomolecules · 2025Article
- Protective role of MJournal of molecular medicine (Berlin, Germany) · 2024Article
- Allosteric Modulation of Muscarinic Receptors by Cholesterol, Neurosteroids and Neuroactive Steroids.International journal of molecular sciences · 2022Review
- Histamine via histamine H1 receptor enhances the muscarinic receptor-induced calcium response to acetylcholine in an enterochromaffin cell model.Clinical and experimental pharmacology & physiology · 2022Article
- A cryptic pocket in Ebola VP35 allosterically controls RNA binding.Nature communications · 2022Article
- Review
- Current Advances in Allosteric Modulation of Muscarinic Receptors.Biomolecules · 2020Review
- Dangerous Liaisons: Tau Interaction with Muscarinic Receptors.Current Alzheimer research · 2020Review
- Widespread Changes in Positive Allosteric Modulation of the Muscarinic M1 Receptor in Some Participants With Schizophrenia.The international journal of neuropsychopharmacology · 2019Article
- Structure-based discovery of selective positive allosteric modulators of antagonists for the MProceedings of the National Academy of Sciences of the United States of America · 2018Article
- Potential drug targets and treatment of schizophrenia.Inflammopharmacology · 2017Review
- The First Negative Allosteric Modulator for Dopamine DMolecular pharmacology · 2017Review
- Structural Insight into Specificity of Interactions between Nonconventional Three-finger Weak Toxin from Naja kaouthia (WTX) and Muscarinic Acetylcholine Receptors.The Journal of biological chemistry · 2015Article
- Long-term activation upon brief exposure to xanomleline is unique to M1 and M4 subtypes of muscarinic acetylcholine receptors.PloS one · 2014Article
- Article
- On homology modeling of the M₂ muscarinic acetylcholine receptor subtype.Journal of computer-aided molecular design · 2013Article
- Molecular properties of muscarinic acetylcholine receptors.Proceedings of the Japan Academy. Series B, Physical and biological sciences · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
An allosteric modulator is a ligand that binds to an allosteric site on the receptor and changes receptor conformation to produce increase (positive cooperativity) or decrease (negative cooperativity) in the binding or action of an orthosteric agonist (e.g., acetylcholine). Since the identification of gallamine as the first allosteric modulator of muscarinic receptors in 1976, this unique mode of receptor modulation has been intensively studied by many groups. This review summarizes over 30 years of research on the molecular mechanisms of allosteric interactions of drugs with the receptor and for new allosteric modulators of muscarinic receptors with potential therapeutic use. Identification of positive modulators of acetylcholine binding and function that enhance neurotransmission and the discovery of highly selective allosteric modulators are mile-stones on the way to novel therapeutic agents for the treatment of schizophrenia, Alzheimer's disease and other disorders involving impaired cognitive function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.